Literature DB >> 2930529

Anti-liver-kidney microsome antibody type 1 recognizes human cytochrome P450 db1.

M Gueguen1, A M Yamamoto, O Bernard, F Alvarez.   

Abstract

Anti-liver-kidney microsome antibody type 1 (LKM1), present in the sera of a group of children with autoimmune hepatitis, was recently shown to recognize a 50 kDa protein identified as rat liver cytochromes P450 db1 and db2. High homology between these two members of the rat P450 IID subfamily and human P450 db1 suggested that anti-LKM1 antibody is directed against this human protein. To test this hypothesis, a human liver cDNA expression library in phage lambda GT-11 was screened using rat P450 db1 cDNA as a probe. Two human cDNA clones were found to be identical to human P450 db1 by restriction mapping. Immunoblot analysis using as antigen, the purified fusion protein from one of the human cDNA clones showed that only anti-LKM1 with anti-50 kDa reactivity recognized the fusion protein. This fusion protein was further used to develop an ELISA test that was shown to be specific for sera of children with this disease. These results: 1) identify the human liver antigen recognized by anti-LKM1 auto-antibodies as cytochrome P450 db1, 2) allow to speculate that mutation on the human P450 db1 gene could alter its expression in the hepatocyte and make it auto-antigenic, 3) provide a simple and specific diagnostic test for this disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2930529     DOI: 10.1016/0006-291x(89)90027-2

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

Review 1.  Xenobiotic-metabolizing enzymes as autoantigens in human autoimmune disorders. An update.

Authors:  E Boitier; P Beaune
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Detection of liver kidney microsomal type 1 antibody using molecularly based immunoassays.

Authors:  N Kerkar; Y Ma; E T Davies; P Cheeseman; G Mieli-Vergani; D Vergani
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

Review 3.  Genetic bases of autoimmune hepatitis.

Authors:  Albert J Czaja; Derek G Doherty; Peter T Donaldson
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

4.  Dextromethorphan phenotypes in paediatric patients with autoimmune hepatitis.

Authors:  E Jacqz-Aigrain; J Laurent; F Alvarez
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

5.  Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes.

Authors:  R Klein; U M Zanger; T Berg; U Hopf; P A Berg
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

6.  LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase.

Authors:  M P Manns; K J Griffin; K F Sullivan; E F Johnson
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

7.  Cytochrome P450IID6 recognized by LKM1 antibody is not exposed on the surface of hepatocytes.

Authors:  A M Yamamoto; C Mura; C De Lemos-Chiarandini; R Krishnamoorthy; F Alvarez
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

8.  Anti-LKM-1 antibodies determined by use of recombinant P450 2D6 in ELISA and western blot and their association with anti-HCV and HCV-RNA.

Authors:  R Seelig; M Renz; G Bünger; H Schröter; H P Seelig
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

Review 9.  Influence of genes, sex, age and environment on the onset of autoimmune hepatitis.

Authors:  Kathie Béland; Pascal Lapierre; Fernando Alvarez
Journal:  World J Gastroenterol       Date:  2009-03-07       Impact factor: 5.742

10.  Study of CYP2D6 gene in children with autoimmune hepatitis and P450 IID6 autoantibodies.

Authors:  A M Yamamoto; C Mura; M G Morales; O Bernard; R Krishnamoorthy; F Alvarez
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.